OBJECTIVE: Significant evidence supports a genetic contribution to the development of posttraumatic stress disorder (PTSD). Three previous studies have demonstrated an association between PTSD and the nine repeat allele of the 3' untranslated region (3'UTR) variable number tandem repeat (VNTR) in the dopamine transporter (DAT, rs28363170). Recently a novel, functionally significant C/T single-nucleotide polymorphism (SNP) in the 3'UTR (rs27072) with putative interactions with the 3'VNTR, has been identified. To provide enhanced support for the role of DAT and striatal dopamine regulation in the development of PTSD, this study examined the impact of a haplotype defined by the C allele of rs27072 and the nine repeat allele of the 3'VNTR on PTSD diagnosis in young trauma-exposed children. METHODS: DAT haplotypes were determined in 150 trauma-exposed 3-6 year-old children. PTSD was assessed with a semistructured interview. After excluding double heterozygotes, analysis was performed on 143 total subjects. Haplotype was examined in relation to categorical and continuous measures of PTSD, controlling for trauma type and race. Additional analysis within the two largest race categories was performed, as other means of controlling for ethnic stratification were not available. RESULTS: The number of haplotypes (0, 1, or 2) defined by the presence of the nine repeat allele of rs28363170 (VNTR in the 3'UTR) and the C allele of rs27072 (SNP in the 3'UTR) was significantly associated with both the diagnosis of PTSD and total PTSD symptoms. Specifically, children with one or two copies of the haplotype had significantly more PTSD symptoms and were more likely to be diagnosed with PTSD than were children without this haplotype. CONCLUSIONS: These findings extend previous findings associating genetic variation in the DAT with PTSD. The association of a haplotype in DAT with PTSD provides incremental traction for a model of genetic vulnerability to PTSD, a specific underlying mechanism implicating striatal dopamine regulation, and insight into potential future personalized interventions.
OBJECTIVE: Significant evidence supports a genetic contribution to the development of posttraumatic stress disorder (PTSD). Three previous studies have demonstrated an association between PTSD and the nine repeat allele of the 3' untranslated region (3'UTR) variable number tandem repeat (VNTR) in the dopamine transporter (DAT, rs28363170). Recently a novel, functionally significant C/T single-nucleotide polymorphism (SNP) in the 3'UTR (rs27072) with putative interactions with the 3'VNTR, has been identified. To provide enhanced support for the role of DAT and striatal dopamine regulation in the development of PTSD, this study examined the impact of a haplotype defined by the C allele of rs27072 and the nine repeat allele of the 3'VNTR on PTSD diagnosis in young trauma-exposed children. METHODS:DAT haplotypes were determined in 150 trauma-exposed 3-6 year-old children. PTSD was assessed with a semistructured interview. After excluding double heterozygotes, analysis was performed on 143 total subjects. Haplotype was examined in relation to categorical and continuous measures of PTSD, controlling for trauma type and race. Additional analysis within the two largest race categories was performed, as other means of controlling for ethnic stratification were not available. RESULTS: The number of haplotypes (0, 1, or 2) defined by the presence of the nine repeat allele of rs28363170 (VNTR in the 3'UTR) and the C allele of rs27072 (SNP in the 3'UTR) was significantly associated with both the diagnosis of PTSD and total PTSD symptoms. Specifically, children with one or two copies of the haplotype had significantly more PTSD symptoms and were more likely to be diagnosed with PTSD than were children without this haplotype. CONCLUSIONS: These findings extend previous findings associating genetic variation in the DAT with PTSD. The association of a haplotype in DAT with PTSD provides incremental traction for a model of genetic vulnerability to PTSD, a specific underlying mechanism implicating striatal dopamine regulation, and insight into potential future personalized interventions.
Authors: Yair Bar-Haim; Yael Holoshitz; Sharon Eldar; Tahl I Frenkel; David Muller; Dennis S Charney; Daniel S Pine; Nathan A Fox; Ilan Wald Journal: Am J Psychiatry Date: 2010-04-15 Impact factor: 18.112
Authors: Helen Link Egger; Alaattin Erkanli; Gordon Keeler; Edward Potts; Barbara Keith Walter; Adrian Angold Journal: J Am Acad Child Adolesc Psychiatry Date: 2006-05 Impact factor: 8.829
Authors: Dean G Kilpatrick; Karestan C Koenen; Kenneth J Ruggiero; Ron Acierno; Sandro Galea; Heidi S Resnick; John Roitzsch; John Boyle; Joel Gelernter Journal: Am J Psychiatry Date: 2007-11 Impact factor: 18.112
Authors: Joanne Voisey; Christopher D Swagell; Ian P Hughes; C Phillip Morris; Angela van Daal; Earnest P Noble; Burnett Kann; Karen A Heslop; Ross McD Young; Bruce R Lawford Journal: Depress Anxiety Date: 2009 Impact factor: 6.505
Authors: Megan L Fitzgerald; Suham A Kassir; Mark D Underwood; Mihran J Bakalian; J John Mann; Victoria Arango Journal: Neuropsychopharmacology Date: 2016-07-12 Impact factor: 7.853
Authors: Kenneth Blum; M C Gondré-Lewis; E J Modestino; L Lott; D Baron; D Siwicki; T McLaughlin; A Howeedy; M H Krengel; M Oscar-Berman; P K Thanos; I Elman; M Hauser; L Fried; A Bowirrat; R D Badgaiyan Journal: Mol Neurobiol Date: 2019-05-23 Impact factor: 5.590
Authors: Jonathon R Howlett; Laura Campbell-Sills; Sonia Jain; Steven G Heeringa; Matthew K Nock; Xiaoying Sun; Robert J Ursano; Murray B Stein Journal: J Trauma Stress Date: 2018-11-21